Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.51 |
| ▸ | CTSS | P25774 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205184 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL1487792 | 1.00 | CTSK (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL2191093 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28031453 | 0.98 | CTSK (0.50) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL376450 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL47004 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL918952 | 0.95 | FOLH1 (0.53) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL30395713 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL28376761 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A | |
| SCHEMBL6751878 | 0.94 | FOLH1 (0.51) | CTSKCTSSMEN1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731602-A1 | NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS | OZ Biosciences (FR) | 2026-04-29 | — | — | EP | disclosed |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| CN-121342737-A | Preparation method of barofloxacin key intermediate 3-methylaminopiperidine dihydrochloride | 江苏联环药业股份有限公司 | 2026-01-16 | — | — | CN | disclosed |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | DESIGN THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4539839-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| EP-4539842-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024261311-A1 | NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS | OZ BIOSCIENCES (FR) | 2024-12-26 | — | — | WO | disclosed |
| EP-4480943-A1 | NEW CLASS OF LIPIDS FOR DELIVERING ACTIVE INGREDIENTS INTO CELLS | Oz Biosciences (FR) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2024-02-15 | — | — | US | disclosed |
| EP-1290024-A1 | GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2003-03-12 | — | — | EP | disclosed |
| US-20020028767-A1 | Glucose dependent release of insulin from glucose sensing insulin derivatives | NOVO NORDISK A/S (DK) | 2002-03-07 | — | — | US | disclosed |
| WO-2001092334-A1 | GLUCOSE DEPENDENT RELEASE OF INSULIN FROM GLUCOSE SENSING INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2001-12-06 | — | — | WO | disclosed |
| CN-1228771-A | 1, 3-diheterocyclic metalloprotease inhibitors | PROCTER & GAMBLE (US) | 1999-09-15 | — | — | CN | disclosed |
| US-5710324-A | AMINE CONTAINING COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1998-01-20 | — | — | US | disclosed |
| US-5508432-A | TREATING GASTROINTESTINAL DISORDERS, CENTRAL NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1996-04-16 | — | — | US | disclosed |
| WO-1996001840-A1 | CATIONIC LIPIDS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS | GILEAD SCIENCES, INC. (US) | 1996-01-25 | — | — | WO | disclosed |
| US-5380872-A | Appetite suppresant, gall bladder disorders, CNS disorders | GLAXO INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-5318992-A | Administering for the treatment of hypotensive conditions and shock | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0446699-A1 | Inhibitors of nitric oxide biosynthesis | MERRELL PHARMACEUTICALS INC. (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | CTSK 1751/4885CTSS 1316/4885MEN1 348/4885 |
| US-20020028767-A1 | Glucose dependent release of insulin from glucose sensing insulin derivatives | GPR119, IRS1, IAPP | CTSK 3522/4885CTSS 4407/4885MEN1 598/4885 |
| US-20250368628-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | CLN6, GATAD2B, MITF | CTSK 3830/4885CTSS 4237/4885MEN1 3157/4885 |
| US-20240050576-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, GRN, F13B | CTSK 3214/4885CTSS 3591/4885MEN1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.